Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

Pantoprazole (PPZ) 抑制肿瘤细胞的增殖，促进细胞凋亡，并降低HIF-1α蛋白的表达[2]。它还影响SGC-7901细胞中HIF-1α的细胞内分布，这可能是其对癌细胞化疗增敏效应的机制之一[3]。

在PPZ处理后，癌细胞中可见选择性的细胞凋亡现象，伴随着细胞外信号调节激酶的失活。相比之下，正常胃粘膜细胞通过过表达抗凋亡调节因子，包括HSP70和HSP27，显示出对PPZ诱导的凋亡的抵抗力。在裸鼠异种移植模型中，PPZ的投给显著抑制了肿瘤生成，并诱导了大规模的肿瘤细胞凋亡[4]。

Pantoprazole sodium salts are resuspended in normal saline (0.85%) at 5 mg/ml immediately prior to use. When the SGC-7901 cells have reached 60–70% confluence, PPZ is added at a final concentration of 20 µg/ml, and the cells are cultured for additional experiments. For example, The SGC-7901 cells are seeded in 100 µl of medium per well, at a density of 1×104/well, in 96-well plates and treated with PPZ for 24 h. (Only for Reference)